Brinker Capital Investments LLC grew its position in shares of Guardant Health, Inc. (NASDAQ:GH – Get Rating) by 96.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 17,687 shares of the company’s stock after acquiring an additional 8,694 shares during the quarter. Brinker Capital Investments LLC’s holdings in Guardant Health were worth $952,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds have also recently bought and sold shares of GH. Capital International Investors boosted its holdings in Guardant Health by 71.0% during the 1st quarter. Capital International Investors now owns 5,081,624 shares of the company’s stock worth $336,607,000 after acquiring an additional 2,110,240 shares during the last quarter. Pictet Asset Management SA raised its stake in shares of Guardant Health by 206.7% during the 2nd quarter. Pictet Asset Management SA now owns 1,034,652 shares of the company’s stock worth $41,738,000 after purchasing an additional 697,281 shares during the period. ARK Investment Management LLC bought a new stake in shares of Guardant Health during the 3rd quarter worth $29,182,000. Ensign Peak Advisors Inc raised its stake in shares of Guardant Health by 1,394.7% during the 1st quarter. Ensign Peak Advisors Inc now owns 312,084 shares of the company’s stock worth $20,672,000 after purchasing an additional 291,204 shares during the period. Finally, Integral Health Asset Management LLC raised its stake in shares of Guardant Health by 285.3% during the 2nd quarter. Integral Health Asset Management LLC now owns 385,291 shares of the company’s stock worth $15,543,000 after purchasing an additional 285,291 shares during the period. 90.43% of the stock is owned by hedge funds and other institutional investors.
Guardant Health Stock Up 0.1 %
Shares of GH opened at $31.70 on Monday. The firm has a market cap of $3.25 billion, a P/E ratio of -5.35 and a beta of 0.83. The stock has a 50 day simple moving average of $38.42 and a two-hundred day simple moving average of $46.49. The company has a debt-to-equity ratio of 6.82, a current ratio of 6.46 and a quick ratio of 6.10. Guardant Health, Inc. has a 1 year low of $24.63 and a 1 year high of $78.34.
Wall Street Analyst Weigh In
A number of equities research analysts have recently commented on the company. Stephens lowered their target price on Guardant Health from $99.00 to $90.00 and set an “overweight” rating on the stock in a research note on Monday, November 7th. Craig Hallum assumed coverage on Guardant Health in a research note on Wednesday, October 19th. They issued a “buy” rating and a $88.00 price objective on the stock. The Goldman Sachs Group lowered their price objective on Guardant Health from $80.00 to $70.00 and set a “buy” rating on the stock in a research note on Friday, November 4th. BTIG Research lowered their price objective on Guardant Health from $80.00 to $60.00 in a research note on Friday, December 16th. Finally, Cowen lowered their price objective on Guardant Health from $110.00 to $83.00 in a research note on Friday, November 4th. One research analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, Guardant Health currently has a consensus rating of “Moderate Buy” and a consensus target price of $90.39.
Insider Buying and Selling at Guardant Health
In other Guardant Health news, insider Kumud Kalia sold 3,125 shares of the business’s stock in a transaction that occurred on Tuesday, November 15th. The stock was sold at an average price of $51.87, for a total value of $162,093.75. Following the completion of the sale, the insider now owns 20,135 shares in the company, valued at $1,044,402.45. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 5.90% of the company’s stock.
Guardant Health Company Profile
Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients.
- Get a free copy of the StockNews.com research report on Guardant Health (GH)
- CVS Health is Growing into an Integrated Healthcare Organization
- Is C3.ai Stock a ChatGPT Artificial Intelligence Play?
- NVIDIA Outlook Improving: Watchlist Candidate for 2023
- Which Wireless Stock Should You Buy in 2023?
- Is Virgin Galactic Stock Preparing for Lift-Off?
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.